These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 15796191

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. The role of bisphosphonates in breast cancer.
    Coleman RE.
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [Abstract] [Full Text] [Related]

  • 26. Optimal management of metastatic bone disease.
    Major P.
    Eur J Oncol Nurs; 2007 Dec; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I.
    Clin Cancer Res; 2008 Jul 15; 14(14):4658-66. PubMed ID: 18628481
    [Abstract] [Full Text] [Related]

  • 29. Maxilla osseus sequestre and oral exposure: effects of the treatment of multiple myeloma with bisphosphonates.
    Lobato JV, Rodrigues JM, Cavaleiro MV, Lobato JM, Xavier L, Santos JD, Maurício AC.
    Acta Med Port; 2007 Jul 15; 20(2):185-92. PubMed ID: 17868526
    [Abstract] [Full Text] [Related]

  • 30. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M.
    Przegl Lek; 2002 Jul 15; 59(1):37-42. PubMed ID: 12108045
    [Abstract] [Full Text] [Related]

  • 31. [Bone-related events in breast cancer].
    Kurebayashi J.
    Clin Calcium; 2008 Apr 15; 18(4):447-54. PubMed ID: 18379025
    [Abstract] [Full Text] [Related]

  • 32. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K, Katsouda E, Stathopoulou E, Vlahos L.
    Cancer Treat Rev; 2005 Jun 15; 31(4):303-11. PubMed ID: 16039956
    [Abstract] [Full Text] [Related]

  • 33. Bisphosphonate therapy for patients with breast carcinoma.
    Plunkett TA, Rubens RD.
    Cancer; 2003 Feb 01; 97(3 Suppl):854-8. PubMed ID: 12548586
    [Abstract] [Full Text] [Related]

  • 34. Emerging role of bisphosphonates in the clinic--antitumor activity and prevention of metastasis to bone.
    Lipton A.
    Cancer Treat Rev; 2008 Feb 01; 34 Suppl 1():S25-30. PubMed ID: 18486347
    [Abstract] [Full Text] [Related]

  • 35. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
    Clines GA, Guise TA.
    Endocr Relat Cancer; 2005 Sep 01; 12(3):549-83. PubMed ID: 16172192
    [Abstract] [Full Text] [Related]

  • 36. Skeletal complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates.
    Green JR.
    Acta Oncol; 2005 Sep 01; 44(3):282-92. PubMed ID: 16076701
    [Abstract] [Full Text] [Related]

  • 37. Anti-tumor potential of bisphosphonates.
    Green JR.
    Med Klin (Munich); 2000 Oct 15; 95 Suppl 2():23-8. PubMed ID: 11089384
    [Abstract] [Full Text] [Related]

  • 38. Use of bisphosphonates in patients with metastatic bone disease.
    Berenson JR, Lipton A.
    Oncology (Williston Park); 1998 Nov 15; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
    [Abstract] [Full Text] [Related]

  • 39. Bisphosphonates in breast cancer patients with skeletal metastases.
    Shapiro CL.
    Hematol Oncol Clin North Am; 1994 Feb 15; 8(1):153-63. PubMed ID: 8150777
    [Abstract] [Full Text] [Related]

  • 40. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR.
    Cancer Treat Rev; 2005 Feb 15; 31 Suppl 3():19-25. PubMed ID: 16229955
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.